# Werewolf Therapeutics, Inc.: overview

HOWL · Nasdaq · CIK 1785530 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/howl.md) · [Financials](/companies/howl/financials.md) · [Filings](/companies/howl/filings.md) · [Insiders](/companies/howl/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.38)](/filings/0001785530-25-000031.md) | not reported | [(0.40)](/filings/0001785530-26-000012.md) | [(0.40)](/filings/0001785530-26-000019.md) | [(0.36)](/filings/0001785530-25-000031.md) | not reported | [(0.28)](/filings/0001785530-26-000012.md) | [0.08](/filings/0001785530-26-000019.md) |
| Free cash flow | $m | [(12.5) d](/filings/0001785530-25-000031.md) | [(14.4) d](/filings/0001785530-26-000006.md) | [(18.9)](/filings/0001785530-26-000012.md) | [(15.2) d](/filings/0001785530-26-000019.md) | [(15.2) d](/filings/0001785530-25-000031.md) | [(11.0) d](/filings/0001785530-26-000006.md) | not reported | not reported |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(10.94)](/filings/0001785530-23-000009.md) | [(1.86)](/filings/0001785530-24-000012.md) | [(1.05)](/filings/0001785530-25-000008.md) | [(1.63)](/filings/0001785530-26-000006.md) | [(1.33)](/filings/0001785530-26-000006.md) |
| Free cash flow | $m | [(43.4)](/filings/0001785530-23-000009.md) | [(44.2)](/filings/0001785530-24-000012.md) | [(33.4)](/filings/0001785530-25-000008.md) | [(56.4)](/filings/0001785530-26-000006.md) | [(60.3)](/filings/0001785530-26-000006.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/howl/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $859.3k | 2,387,744 |  | Reduced −4,293,563 |
| [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $644.3k | 1,790,089 |  | New +1,790,089 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $438.5k | 1,217,976 |  | Unchanged |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $242.8k | 674,632 |  | Added +158,414 |
| [Lynx1 Capital Management LP](/funds/1910456.md) | 2026-06-30 | $236.7k | 657,786 |  | Unchanged |
| [SPHERA FUNDS MANAGEMENT LTD.](/funds/1496201.md) | 2026-06-30 | $225.6k | 626,810 |  | Unchanged |
| [DC Funds, LP](/funds/1869028.md) | 2026-06-30 | $212.0k | 589,102 |  | Unchanged |
| [Verdad Advisers, LP](/funds/1812822.md) | 2026-06-30 | $125.5k | 348,709 |  | Added +318,949 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $120.9k | 335,815 |  | Reduced −53,672 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $111.8k | 311,502 |  | Added +46,919 |

## Recent filings

[All 448 filings](/companies/howl/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-21 | 09:10 ET | [8-K](/filings/0001193125-26-360059.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-360059 |
| 2026-08-20 | 16:06 ET | [8-K](/filings/0001193125-26-359185.md) | 1.01 Entry into a material agreement | 0001193125-26-359185 |
| 2026-07-31 | 07:10 ET | [10-Q](/filings/0001785530-26-000019.md) | Quarterly report, period 2026-06-30 | 0001785530-26-000019 |
| 2026-07-31 | 07:06 ET | [8-K](/filings/0001785530-26-000018.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001785530-26-000018 |
| 2026-07-02 | 20:26 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000187.md) | Ownership report, active investor, amended | 0001346824-26-000187 |
| 2026-06-26 | 17:39 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000185.md) | Ownership report, active investor, amended | 0001346824-26-000185 |
| 2026-06-22 | 19:02 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000180.md) | Ownership report, active investor, amended | 0001346824-26-000180 |
| 2026-06-15 | 20:16 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000175.md) | Ownership report, active investor, amended | 0001346824-26-000175 |
| 2026-05-14 | 17:23 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000131.md) | Ownership report, active investor, amended | 0001346824-26-000131 |
| 2026-05-12 | 19:56 ET | [SCHEDULE 13D/A](/filings/0001609492-26-000006.md) | Ownership report, active investor, amended | 0001609492-26-000006 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001785530-26-000006.md), filed Mar 27, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1785530
- Tickers: HOWL
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 17:25 ET. No prices; not investment advice.